Veerhealth Care Ltd.: Charting a 'Local to Global' Growth Trajectory with USFDA Approvals

Veerhealth Care Ltd., a company with roots tracing back to 1992 as Niyati Leasing Limited, has undergone a significant transformation, pivoting from investment and finance to the dynamic healthcare and personal care sectors. This strategic evolution, particularly since 2013, has positioned the company as a specialized manufacturer of oral care, cosmetics, and personal care products. The latest investor presentation highlights a period of aggressive expansion and regulatory achievements, underscoring Veerhealth's ambition to become a global player.

The company's Q3 FY26 performance reflects this growth momentum. Revenue from operations surged to 7.26 crore, a substantial increase from 3.84 crore in Q3 FY25. Total income for the quarter stood at 6.97 crore. While 'Other Income' showed a negative figure of 0.29 crore in Q3 FY26, the company's EBITDA for the quarter was 0.94 crore, with a Profit Before Tax (PBT) of 0.49 crore and a Profit After Tax (PAT) of 0.40 crore. These figures demonstrate a robust operational scale-up, even as profitability metrics show some quarterly fluctuations.

Financial Highlights

Note: All figures are converted from Lakhs to Crores for consistency.

Strategic Milestones and Expansion Drive

A cornerstone of Veerhealth's recent strategy is its relentless pursuit of international regulatory compliance. The company successfully secured USFDA clearance for its Drug (OTC) products in June 2025, following an audit in March 2025. This is a monumental achievement for a small-cap Indian company, enabling direct exports to the U.S. and opening doors to other highly regulated international markets. Furthermore, Veerhealth has completed the necessary formalities with the USFDA for products under the medical device category, signaling a clear intent to diversify and strengthen its global healthcare footprint.

To support this ambitious 'Local to Global' vision, Veerhealth is significantly expanding its manufacturing capabilities. In October 2024, the company acquired an additional 30,000 sq. ft. of land adjacent to its Vapi facility, bringing the total plot size to 60,000 sq. ft. with a construction area of 90,000 sq. ft. This expansion is crucial for future manufacturing growth and product diversification. Complementing this, the launch of the Veer Plast division in 2025 represents a strategic backward integration, allowing the company to manufacture its own packaging and components, thereby enhancing quality control and cost-effectiveness.

Market Presence and Future Outlook

Veerhealth's in-house personal care brand, AYUVEER, is gaining traction through an expanded e-commerce presence, now available on platforms like Myntra, Amazon, Flipkart, Nykaa, Glowroad, and Jiomart. This multi-channel approach is vital for reaching a broader consumer base in the competitive personal care market. The company's product portfolio spans a wide range, including oral care (toothpaste, mouthwash), skincare (facewash, creams, serums, lip balms, sunscreens), hair care (shampoos, oils, conditioners), body care (body wash, lotions, bathing salts, hand wash), and health care (syrups, tablets, pain relief oil), along with a dedicated kids' range and microbiome products.

Management's guidance reflects strong confidence in the company's future. Veerhealth projects FY26 revenue between 35-40 crore with a 10% PAT margin. The P&L projections further detail a significant growth trajectory, with Net Sales expected to reach 97.15 crore by FY27-28, accompanied by a PAT margin of 12.24%. These projections are underpinned by the company's upgraded manufacturing facilities, USFDA compliance, and strategic market penetration efforts. Veerhealth Care Ltd. is clearly focused on leveraging its enhanced capabilities to compete with larger players and establish itself as a leading exporter of OTC and medical device products from India, embodying a disciplined approach to sustained growth and market leadership.